Treatment of ECL cell carcinoids with octreotide LAR

Author： Fykse V.   Sandvik A. K.   Qvigstad G.   Falkmer S. E.   Syversen U.   Waldum H. L.  

Publisher： Informa Healthcare

ISSN： 0036-5521

Source： Scandinavian Journal of Gastroenterology, Vol.39, Iss.7, 2004-07, pp. : 621-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

By Jianu Constantin S.   Fossmark Reidar   Syversen Unni   Hauso ØØyvind   Fykse Vidar   Waldum Helge L.  

Scandinavian Journal of Gastroenterology, Vol. 46, Iss. 4, 2011-04 ,pp. : 456-463

Informa Healthcare

Access to resources Recommend Favorite

Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

By Vilar Lucio  

Pituitary, Vol. 14, Iss. 2, 2011-06 ,pp. : 148-156

Springer Publishing Company

Access to resources Recommend Favorite

Spotlight on Octreotide Long-Acting Release (LAR) in Acromegaly

By McKeage Kate   Cheer Susan   Wagstaff Antona J.  

Treatments in Endocrinology, Vol. 3, Iss. 3, 2004-01 ,pp. : 197-200

Adis International

Access to resources Recommend Favorite

Octreotide in the Treatment of Refractory Diarrhea

By  

Digestion, Vol. 60, Iss. 2, 1999-04 ,pp. : 42-46

Karger

Access to resources Recommend Favorite

Octreotide in the treatment of refractory ascites of cirrhosis

By Kalambokis Georgios   Fotopoulos Andreas   Economou Michael   Tsianos Epameinondas  

Scandinavian Journal of Gastroenterology, Vol. 41, Iss. 1, 2006-01 ,pp. : 118-121

Informa Healthcare

Access to resources Recommend Favorite